Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AZD8931 + anastrozole
- Development stage
- Discontinued
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AZD8931 + anastrozole is a combination therapy consisting of AZD8931, an orally bioavailable, reversible tyrosine kinase inhibitor of EGFR, HER2, and HER3 signaling, and anastrozole, an aromatase inhibitor. This combination was investigated to determine if adding AZD8931 to endocrine therapy would delay the development of endocrine resistance in patients with hormone-sensitive advanced breast cancer.
02
Targets
CYP19A1 (Aromatase)EGFR (Epidermal growth factor receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)ERBB3 (Erb-b2 receptor tyrosine kinase 3)
Beyond the preview
Go deeper on AZD8931 + anastrozole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AZD8931 + anastrozole.